Pretzel Therapeutics

Executive Summary

Pretzel Therapeutics is a preclinical-stage biotechnology company developing novel therapies for rare diseases caused by mitochondrial dysfunction. The company's proprietary platform targets the mitochondrial genome and its regulatory mechanisms, employing both gene therapy and small molecule approaches to restore healthy mitochondrial function. Founded in 2021 and headquartered in Cambridge, MA, Pretzel has raised $72.5 million to advance its pipeline. Mitochondrial dysfunction underlies a range of severe inherited metabolic and neurological disorders with high unmet need, positioning Pretzel's technology as a potential transformative solution. The company's strategy focuses on precise modulation of mitochondrial gene expression, aiming to correct the root cause of these diseases rather than merely managing symptoms. With a strong scientific foundation and a clear translational path, Pretzel is poised to enter the clinic in the near term.

Upcoming Catalysts (preview)

• TBDIND Filing for Lead Program60% success
• TBDPreclinical Proof-of-Concept Data Release80% success
• TBDSeries C Financing or Strategic Partnership70% success